Journal
EPILEPSIA
Volume 54, Issue -, Pages 93-98Publisher
WILEY
DOI: 10.1111/epi.12289
Keywords
Refractory status epilepticus; Seizure; Allopregnanolone; Neurosteroid; Allosteric modulator; Extrasynaptic GABA(A) receptor
Categories
Funding
- People Against Childhood Epilepsy (P.A.C.E.)
- Children's Miracle Network
- National Institute of Neurological Disorders and Stroke [NS072094, NS079202]
Ask authors/readers for more resources
Benzodiazepines are the current first-line standard-of-care treatment for status epilepticus but fail to terminate seizures in about one third of cases. Synaptic GABA(A) receptors, which mediate phasic inhibition in central circuits, are the molecular target of benzodiazepines. As status epilepticus progresses, these receptors are internalized and become functionally inactivated, conferring benzodiazepine resistance, which is believed to be a major cause of treatment failure. GABA(A) receptor positive allosteric modulator neuroactive steroids, such as allopregnanolone, also potentiate synapticGABA(A) receptors, but in addition they enhance extrasynapticGABA(A) receptors that mediate tonic inhibition. ExtrasynapticGABA(A) receptors are not internalized, and desensitization of these receptors does not occur during continuous seizures in status epilepticus models. Here we review the broad-spectrum antiseizure activity of allopregnanolone in animal seizure models and the evidence for its activity in models of status epilepticus. We also demonstrate that allopregnanolone inhibits ongoing behavioral and electrographic seizures in a model of status epilepticus, even when there is benzodiazepine resistance. Parenteral allopregnanolone may provide an improved treatment for refractory status epilepticus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available